Sonata Therapeutics

Listen in to this episode of Careers in Discovery to learn more about Sonata and our CEO Volker Herrmann, MD career trajectory and approach to leadership. 

Listen to some great insights from our CEO Volker Herrmann, MD!

Celebrating Summer at Sonata Therapeutics! At Sonata, we believe in fostering a vibrant team culture, and our recent summer outing was a testament to just that! 🎉 Yesterday our team and their families came together for an afternoon filled with fun, laughter, and bonding. From competitive games to delicious food, it was a time to remember. Our outing not only strengthened friendships but also reinforced our commitment to collaboration and innovation. A huge shout-out to our culture commitment team who helped organize this fantastic event and making it such a success. Here's to more memorable moments ahead at Sonata! #TeamBuilding #CompanyCulture #SummerOuting #Sonata #WorkHardPlayHard

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be part of the #FlagshipFounded ecosystem of companies making #biggerleaps for patients.

Sonata’s CEO, Volker Herrmann, recently shared his insights in Pharma’s Almanac

The Champalimaud Centre is one of Europe’s leading oncology research institutes and Sonata Therapeutics is excited to be working with them to translate the immense potential of our Network Medicine SNT-3012 to the clinic. Sonata’s scientific leaders had the opportunity to strategize with the team, review data and see firsthand how SNT-3012 transforms the tumor microenvironment, resulting in the broad activation of human tumor-specific T cells. Sonata looks forward to continuing this important collaboration with Champalimaud to bridge the gap between basic science and clinical application and rapidly bring SNT-3012 to cancer patients in need.

Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below. 

Our team had an exciting and productive time at #AACR24. Not only was it great to connect with global #cancer leaders and hear about all of the new research being done to cure patients of cancer, but it was also rewarding to see how our differentiated Network Medicines may address many of the key issues in cancer therapy that we are all trying to tackle. Already looking forward to next year

We're pleased to announce a research collaboration with the Champalimaud Foundation for the development of SNT-3012 in pancreatic and colorectal cancers. Read more: https://lnkd.in/eeVRji26   #CancerResearch #Cancer #Health #research

Hear from the CEOs and leaders of #FlagshipFounded companies as they share the latest platform and pipeline updates, the therapeutic areas they’re focused on, new & expanded partnerships, how they’re building company culture, and what’s ahead for 2024. Watch all the latest CEO Chats here: bit.ly/48LWm3t 🔹 Fabrice Chouraqui, CEO, Cellarity  🔹 Steve Harr, CEO, Sana Biotechnology, Inc.  🔹 Volker Herrmann, MD, CEO, Sonata Therapeutics  🔹 John Lepore, CEO, ProFound Therapeutics  🔹 Michael Nally, CEO, Generate:Biomedicines  🔹 Guillaume Pfefer, CEO, Sail Biomedicines  🔹 Lovisa Afzelius, Co-founder and CEO, Metaphore Biotechnologies  🔹 Christopher Austin, CEO, Vesalius Therapeutics  🔹 Jason Gardner, CEO, Ampersand Biomedicines  🔹 Jason Park, CEO, Empress Therapeutics  🔹 Eric Shaff, CEO, Seres Therapeutics  🔹 Lovisa Afzelius, Co-founder and CEO, Apriori Bio  🔹 Margo Georgiadis, Co-founder and CEO, Montai Health  🔹 Adrian Gottschalk, CEO, Foghorn Therapeutics Inc.  🔹 Steve Hahn, CEO, Harbinger Health  🔹 Mahesh Karande, President and CEO, Omega Therapeutics  🔹 Jacob Rubens, President, Quotient Therapeutics  🔹 Michelle Werner, CEO, Alltrna #FlagshipJPM #JPM24 #JPM2024